Next, to explore anticancer activity of anti-CD19 autologous CAR T and allogeneic CAR NK cells in vivo, we implanted lymphoblastoid tumor cells (LCL) subcutaneously into NSG mice [35–37], modeling human B cell lymphoma therapy with either autologous CAR T cells [38] or allogeneic CAR NK cells [11]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.